Vinpocetine is a derivative of vincamine, which is an extract of the periwinkle plant. Vinpocetine improves thinking quickly by improving blood flow in the brain, increasing production of brain cell ATP (ATP is the cellular energy molecule), and by increasing utilization of glucose and oxygen.1
One double-blind study of healthy volunteers without any signs of dementia or Alzheimer’s disease showed incredible cognitive thinking improvement only one hour after taking 40 mg of vinpocetine. Volunteers took a computer-administered cognitive function test before and after being given vinpocetine. When given vinpocetine, they showed better than 35% improvement over their scores before taking vinpocetine.2
The reason for this huge improvement in such a short amount of time relates to the way vinpocetine works in the brain. Vinpocetine improves circulation in your brain, feeding all the cells including neurons. It ensures brain cells get the right amount of food in the form of glucose and enough oxygen to metabolize it properly. And finally, it assures that ATP (the molecule that converts glucose into energy) is functioning at peak performance.
When your brain’s energy mechanism is functioning at peak performance levels, so will your brain … and so will you. Peak brain performance translates into improved overall cognitive functioning. This is how vinpocetine makes you smarter!
Other physiological effects and side effects
Vinpocetine is used to treat acute or chronic eye diseases of various origins and sensorineural hearing impairment. The Gedeon Richter company has funded more than 100 studies on vinpocetine. The incidence of side effects in humans using vinpocetine orally is less than 1% of a study’s participants, with the unwanted effects usually disappearing with continued use.
- Hadjiev D, Yancheva S. (1976) Rheoencephalographic and psychological studies with ethyl apovincaminate in cerebral vascular insufficiency. Arzneim-Forsch, 26(10a): 1947-1950.
- Subhan, Z., Hindmarch, I. “Psychopharmacological Effects of Vinpocetine in Normal Healthy Volunteers.” European Journal of Clinical Pharmacology. 1985, Vol. 28, pp. 567-71.